Citizens' opinions and experiences related to costs and reimbursements for medications in times of retrenchment: cross-sectional population surveys in 2015 and 2017

Trends in the use of psychotropics in older people with dementia: interrupted time series of Finnish clinical guidelines of behavioural and psychological symptoms of dementia

BACKGROUND

Up to 90% of people with dementia experience behavioural and psychological symptoms of dementia (BPSD) as part of their illness. Psychotropics are not recommended as the first-line treatment of BPSD because older people are more prone to adverse reactions. In this study, we evaluate the impact of the Finnish clinical guidelines of BPSD (published in 2017) on psychotropic use in people with dementia.

METHODS

This study is based on Finnish Prescription Register data from 2009 to 2020. The data included all community-dwelling Finnish people aged ≥65 and who had anti-dementia medication purchases (n = 217,778). We used three-phased interrupted time series design to evaluate the changes in levels and trends of monthly (n = 144) psychotropic user rates compared with the predicted trends. In addition, we evaluated the changes in levels and trends of monthly new psychotropic user rates.

RESULTS

The level of monthly psychotropic user rate decreased non-significantly during the intervention period (β -0.057, P = 0.853), and during the post-intervention period, there was an increase in the level (β 0.443, P = 0.091) and slope (β 0.199, P = 0.198), but not statistically significant. The level of monthly new psychotropic user rate (β -0.009, P = 0.949) during the intervention period and the level (β 0.044, P = 0.714) and slope (β 0.021, P = 0.705) during the post-intervention period were almost unchanged.

CONCLUSIONS

Results may indicate possible challenges in deprescribing and better adherence to the guidelines at the beginning of BPSD treatment. Further research into the barriers to implement BPSD guidelines and the availability of non-pharmacological treatments is needed.

Socioeconomic inequalities in insulin initiation among individuals with type 2 diabetes - A quasi-experimental nationwide register study

Background

Inequalities in access to care can translate to or strengthen existing inequalities in health if people of lower socioeconomic positions do not have equal access to care. I study insulin initiation among individuals with type 2 diabetes and examine whether a reform increasing the co-payment of non-insulin antidiabetics in Finland in 2017 had an inequitable effect on the initiation. In the treatment of type 2 diabetes, insulin is recommended only in later stages and remains covered by the National Health Insurance at a rate of 100%.

Data and methods

I evaluated the effect of the reform with Cox proportional hazard modelling using nationwide person-level register data from 2011 to 2019. Exploiting a quasi-experimental design rising from the introduction of the reform allows for consideration of causality.

Results

I found that the risk of insulin initiation was lower in the later years of the study period. Additionally, individuals in lower socioeconomic positions had a higher risk of initiation. However, I did not find inequalities in how the reform affected the risk of insulin initiation between income quintiles.

Conclusions

Co-payments are unlikely to be the most influential factor behind persisting inequalities in insulin initiation among individuals with type 2 diabetes in Finland. Lower risk in the later years aligns with developing treatment practices of type 2 diabetes.

•

Individuals with type 2 diabetes in lower socioeconomic positions had a higher risk of insulin initiation.

•

The risk of insulin initiation was lower in the later years of the study period (2011-2019) in all income quintiles.

•

No inequalities in the impact of the co-payment increase in non-insulin antidiabetics in insulin initiation were found.